Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007004715) METHOD AND COMPOSITION TO INDIVIDUALIZE LEVODOPA/CARBIDOPA THERAPY USING A BREATH TEST
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/004715 International Application No.: PCT/JP2006/313529
Publication Date: 11.01.2007 International Filing Date: 30.06.2006
IPC:
A61K 51/00 (2006.01) ,A61K 31/198 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
Applicants:
OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo 1018535, JP (AllExceptUS)
CAMBRIDGE ISOTOPE LABORATORIES, INC. [US/US]; 50 Frontage Road, Andover, MA 01810-5413, US (AllExceptUS)
MODAK, Anil, S. [US/US]; US (UsOnly)
KUROGI, Yasuhisa [JP/US]; US (UsOnly)
Inventors:
MODAK, Anil, S.; US
KUROGI, Yasuhisa; US
Agent:
SAEGUSA, Eiji ; Kitahama TNK Building 1-7-1, Doshomachi Chuo-ku, Osaka-shi Osaka 541-0045, JP
Priority Data:
60/695,50330.06.2005US
Title (EN) METHOD AND COMPOSITION TO INDIVIDUALIZE LEVODOPA/CARBIDOPA THERAPY USING A BREATH TEST
(FR) PROCÉDÉ ET COMPOSITION POUR PERSONNALISATION DU TRAITEMENT LÉVODOPA/CARBIDOPA AU MOYEN D’UN TEST RESPIRATOIRE
Abstract:
(EN) The present invention relates, generally to a method of determining and assessing L-3,4-dihydroxyphenylalanine (a.k.a., Levodopa; L-dopa; or LD) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled substrate, such as levodopa. The present invention is useful as an in vivo phenotype assay for individualizing LD/ Carbidopa(CD) therapy in Parkinsons disease patients by optimizing the dose and timing of the dose of dopamine decarboxylase (DDC) inhibitor like CD for systemic suppression of dopamine metabolism .by evaluating DDC enzyme activity using the metabolite 13CO2 in expired breath.
(FR) La présente invention concerne un procédé de détermination et d’évaluation de la capacité métabolique liée à la L-3,4-dihydroxyphénylalanine (alias Lévodopa, L-dopa ou LD) chez un sujet mammifère au moyen d’un essai respiratoire en déterminant la quantité relative de 13CO2 exhalée par le sujet auquel est administré par voie intraveineuse ou orale un substrat étiqueté 13C tel que la lévodopa. L’invention peut être utilisée en tant qu’essai phénotypique in vivo pour personnaliser le traitement LD/ Carbidopa(CD) de patients atteints de la maladie de Parkinson en optimisant le dosage et le moment d’administration d’un inhibiteur de la dopamine décarboxylase (DDC) tel que CD pour la suppression systémique du métabolisme de la dopamine par l’évaluation de l’activité enzymatique de la DDC au moyen du métabolite 13CO2 de l’air expiré.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1898961ES2450690EP2921181DK1898961